Table 2.
Percentage of CD5‐positive or CD23‐positive cells in CD19‐positive cells immunoglobulin heavy chain variable region (IGHV), IGKV, and IGLV status in chronic lymphocytic leukemia (CLL) patients
| CLL patient | CD5 (%) | CD23 (%) | IGHV | Homology (%) | IGHD | IGHJ | K/L | IGKV/IGLV | IGKJ/LJ | Homology (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| CLL 1 | 98.0 | 85.1 | 1–2 | 94.2 | 2–15 | 4 | K | 3–20(A27) | 2 | 98.8 |
| CLL 2 | 86.2 | 97.4 | 1–3 | 90.0 | 3–9 | 5 | K | 3D‐20(A11) | 2 | 96.2 |
| CLL 3 | 89.7 | 87.5 | 1–8 | 94.2 | 1–1 | 5 | K | 3D‐20(A11) | 2 | 89.1 |
| CLL 4 | 87.1 | 98.0 | 1–8 | 94.9 | 6–13 | 4 | K | 3–11(L6) | 4 | 98.0 |
| CLL 5 | 98.0 | 54.7 | 1–18 | 98.5 | 3–10 | 6 | L | 2–11(V1‐3) | 3 | 92.9 |
| CLL 6 | 73.3 | 97.7 | 1–18 | 99.0 | 2–15 | 6 | L | 1–47(V1‐17) | 3 | 100 |
| CLL 7 | 98.4 | 97.4 | 1–46 | 99.1 | 3–9 | 6 | K | 3D‐20(A11) | 2 | 97.7 |
| CLL 8 | 100 | 69.7 | 1–69 | 98.0 | 5–12 | 6 | L | 3–1(V2‐1) | 4 | 99.5 |
| CLL 9 | 85.9 | 98.0 | 2–5 | 99.4 | 2–2 | 4 | K | 2D‐29(A2) | 1 | 99.3 |
| CLL 10 | 58.0 | 89.3 | 2–70 | 91.6 | 3–10 | 4 | L | 3–21(V2‐14) | 3 | 90.9 |
| CLL 11 | 89.4 | 38.5 | 3–7 | 93.7 | 2–2 | 3 | L | 1–44(V1‐16) | 1 | 96.0 |
| CLL 12 | 100 | 18.2 | 3–7 | 99.3 | 3–9 | 4 | L | 3–21(V2‐14) | 3 | 100 |
| CLL 13 | 51.9 | 40.9 | 3–7 | 87.0 | 4–17 | 3 | K | 1–33(O18) | 4 | 100 |
| CLL 14 | 99.4 | 52.5 | 3–7 | 94.8 | 2–15 | 5 | K | NA | NA | NA |
| CLL 15 | 96.0 | 96.0 | 3–11 | 99.6 | 3–3 | 4 | L | 1–44(V1‐16) | 2 | 98.0 |
| CLL 16 | 91.5 | 63.2 | 3–15 | 94.8 | 2–2 | 2 | L | 3–25(2–17) | 2 | 96.0 |
| CLL 17 | 94.2 | 90.1 | 3–15 | 96.7 | 2–2 | 4 | L | 10–54(V1‐20) | 3 | 83.9 |
| CLL 18 | 43.7 | 97.6 | 3–15 | 93.0 | 6–19 | 4 | L | 3–21(V2‐14) | 3 | 98.0 |
| CLL 19 | 98.2 | 97.3 | 3–21 | 96.3 | 3–10 | 6 | L | 3–19(V2‐13) | 2 | 96.0 |
| CLL 20 | 97.9 | 9.2 | 3–21 | 99.4 | 3–9 | 4 | L | 2–14(V1‐4) | 2 | 94.7 |
| CLL 21 | 32.1 | 35.9 | 3–21 | 99.6 | 2–15 | 5 | L | 2–14(V1‐4) | 2 | 100 |
| CLL 22 | 85.2 | 92.7 | 3–21 | 91.0 | 3–16 | 5 | L | 3–21(V2‐14) | 3 | 97.0 |
| CLL 23 | 100 | 96.6 | 3–21 | 96.0 | 5–21 | 4 | L | 3–21(V2‐14) | 3 | 98.0 |
| CLL 24 | 69.9 | 51.8 | 3–21 | 94.4 | 4–23 | 4 | K | 3–20(A27) | 1 | 95.8 |
| CLL 25 | 47.1 | 14.3 | 3–23 | 88.1 | 1–26 | 4 | L | 3–1(V2‐1) | 2 | 97.0 |
| CLL 26 | 85.0 | 96.0 | 3–23 | 96.6 | 1–26 | 4 | L | 3–21(V2‐14) | 3 | 97.0 |
| CLL 27 | 83.0 | 98.1 | 3–23 | 95.7 | 2–21 | 4 | K | 3–20(A27) | 3 | 95.3 |
| CLL 28 | 100 | 98.2 | 3–23 | 100 | 3–9 | 4 | K | 1–33(O18) | 4 | 100 |
| CLL 29 | 74.0 | 63.5 | 3–23 | 99.1 | 6–19 | 2 | K | 4–1(B3) | 1 | 92.0 |
| CLL 30 | 98.0 | 85.3 | 3–23 | 91.1 | 7–27 | 4 | K | 2–30(A17) | 2 | 91.0 |
| CLL 31 | 95.2 | 99.3 | 3–23 | 92.9 | 2–21 | 6 | L | 1–51(V1‐19) | 5 | 98.8 |
| CLL 32 | 95.2 | 24.7 | 3–30 | 94.7 | 3–22 | 3 | K | 1–37(O14) | 4 | 98.7 |
| CLL 33 | 32.5 | 90.2 | 3–30 | 94.6 | 6–6 | 4 | L | 1–44(V1‐16) | 3 | 92.9 |
| CLL 34 | 42.4 | 93.5 | 3–30 | 85.3 | 2–2 | 5 | L | 1–51(V1‐19) | 3 | 96.7 |
| CLL 35 | 93.2 | 98.2 | 3–30 | 88.0 | 3–3 | 5 | K | 3–11(L6) | 4 | 94.0 |
| CLL 36 | 30.7 | 28.6 | 3–30 | 95.6 | 2–15 | 6 | K | 3–11(L6) | 5 | 100 |
| CLL 37 | 98.0 | 100 | 3–33 | 92.5 | 3–16 | 6 | K | 1D‐17(L14) | 1 | 95.5 |
| CLL 38 | 52.9 | 89.3 | 3–43 | 89.2 | 4–23 | 4 | K | 1D‐17(L14) | 2 | 98.4 |
| CLL 39 | 100 | 98.0 | 3–48 | 98.3 | 3–22 | 4 | L | 3–21(V2‐14) | 1 | 98.0 |
| CLL 40 | 100 | 77.5 | 3–48 | 90.0 | 3–16 | 4 | L | 3–21(V2‐14) | 3 | 96.0 |
| CLL 41 | 44.4 | 41.5 | 3–48 | 91.4 | 7–27 | 4 | K | 2–30(A17) | 6 | 88.2 |
| CLL 42 | 100 | 2.9 | 3–49 | 91.9 | 3–10 | 4 | K | 1–39(O12) | 1 | 95.0 |
| CLL 43 | 100 | 98.0 | 3–53 | 99.0 | 3–10 | 6 | K | 3–11(L6) | 2 | 99.0 |
| CLL 44 | 100 | 91.1 | 3–53 | 95.9 | 1–26 | 2 | K | 3D‐20(A11) | 4 | 92.3 |
| CLL 45 | 89.7 | 100 | 3–64 | 95.7 | 4–17 | 4 | L | 2–14(V1‐4) | 1 | 98.7 |
| CLL 46 | 61.7 | 98.0 | 3–64 | 91.0 | 1–26 | 3 | L | 3–21(V2‐14) | 3 | 92.0 |
| CLL 47 | 36.5 | 78.0 | 3–73 | 91.6 | 3–9 | 4 | K | 2–28(A19) | 4 | 96.0 |
| CLL 48 | 97.5 | 52.5 | 3–74 | 93.0 | 1–1 | 6 | L | 2–23(V1‐7) | 7 | 95.0 |
| CLL 49 | 85.5 | 11.3 | 3–74 | 89.4 | 5–24 | 6 | L | 3–25(V2‐17) | 3 | 94.7 |
| CLL 50 | 36.9 | 64.9 | 4–34 | 96.9 | 6–19 | 4 | L | 2–23(V1‐7) | 2 | 94.4 |
| CLL 51 | 35.9 | 32.8 | 4–34 | 92.2 | NA | NA | L | 3–10(V2‐7) | NA | 91.9 |
| CLL 52 | 98.0 | 98.0 | 4–34 | 94.0 | 6–19 | 5 | L | 1–40(V1‐13) | 2 | 97.2 |
| CLL 53 | 100 | 100 | 4–34 | 94.0 | 2–21 | 5 | L | 3–21(V2‐14) | 1 | 100 |
| CLL 54 | 36.2 | 93.3 | 4–34 | 90.0 | 4–17 | 4 | L | 2–14(V1‐4) | 3 | 90.0 |
| CLL 55 | 52.0 | 29.3 | 4–34 | 92.5 | 3–22 | 1 | K | 2–30(A17) | NA | 97.4 |
| CLL 56 | 78.7 | 82.5 | 4–34 | 86.0 | 3–10 | 4 | K | 3–11(L6) | 4 | 91.5 |
| CLL 57 | 33.0 | 90.0 | 4–34 | 92.3 | 2–15 | 6 | K | 2–28(A19) | 1 | 96.0 |
| CLL 58 | 84.2 | 62.1 | 4–34 | 90.1 | 1–26 | 3 | K | NA | NA | NA |
| CLL 59 | 100 | 94.4 | 4–34 | 98.3 | 5–12 | 6 | K | 1–9(L8) | 3 | 94.0 |
| CLL 60 | 98.0 | 51.0 | 4–34 | 94.6 | 3–22 | 3 | K | 3–11(L6) | 2 | 87.6 |
| CLL 61 | 75.8 | 100 | 4–34 | 88.4 | 1–26 | 6 | K | 2–30(A17) | 2 | 95.7 |
| CLL 62 | 44.3 | 93.8 | 4–34 | 93.0 | 2–21 | 6 | K | 2–28(A19) | 1 | 89.0 |
| CLL 63 | 40.3 | 95.0 | 4–34 | 87.0 | 3–3 | 5 | K | 2–28(A19) | 1 | 93.0 |
| CLL 64 | 80.9 | 98.0 | 4–34 | 99.5 | 7–27 | 4 | K | 3–15(L‐2) | 1 | 99.0 |
| CLL 65 | 86.3 | 95.3 | 4–34 | 97.0 | 7–27 | 4 | K | 1–9(L8) | 4 | 96.0 |
| CLL 66 | 71.8 | 90.9 | 4–34 | 92.0 | 5–18 | 6 | K | 3–11(L6) | 2 | 92.0 |
| CLL 67 | 86.1 | 92.0 | 4–34 | 89.0 | 3–10 | 5 | K | 3D‐15(L16) | 4 | 95.0 |
| CLL 68 | 55.7 | 72.1 | 4–34 | 93.2 | 3–10 | 5 | K | 1–5(L12) | 1 | 98.2 |
| CLL 69 | 58.1 | 98.0 | 4–34 | 90.6 | 2–15 | 6 | K | 1–5(L12) | 2 | 94.1 |
| CLL 70 | 37.9 | 99.4 | 4–34 | 91.0 | 1–26 | 4 | K | 1–5(L12) | 2 | 86.8 |
| CLL 71 | 81.6 | 100 | 4–39 | 94.0 | 1–26 | 4 | L | 3–25(V2‐17) | 1 | 93.9 |
| CLL 72 | 91.2 | 81.5 | 4–39 | 99.7 | 6–13 | 5 | K | 1–39(O12) | 1 | 100 |
| CLL 73 | 82.9 | 48.8 | 4–39 | 98.0 | 6–13 | 5 | K | 1–39(O12) | 2 | 98.0 |
| CLL 74 | 61.5 | 83.1 | 4–4 | 84.7 | 2–8 | 5 | K | 3–20(A27) | 1 | 98.0 |
| CLL 75 | 68.8 | 71.4 | 4–4 | 95.5 | 2–21 | 3 | L | 2–23(V1‐7) | 3 | 96.0 |
| CLL 76 | 43.8 | 63.4 | 4–34 | 92.8 | 6–19 | 2 | L | 1–40(V1‐13) | 3 | 95.1 |
| CLL 77 | 69.1 | 40.9 | 4–61 | 85.4 | 7–27 | 5 | K | 2–30(A17) | 2 | 94.6 |
| CLL 78 | 88.9 | 95.6 | 5–51 | 89.0 | 7–27 | 4 | L | NA | NA | NA |
| CLL 79 | 98.0 | 74.1 | 5–51 | 96.4 | 3–10 | 4 | K | 2–28(A19) | 2 | 100 |
| CLL 80 | 98.2 | 100 | 6–1 | 92.4 | 3–10 | 3 | K | 2–28(A19) | 2 | 94.0 |
All CLL cases were positive for CD5. CD23‐positive cases were 90.0% (72/80). The cut‐off point for CD23‐positivity in CLL cells was ≥30%. Shaded cells indicate CD23 expression <30%. For all IGKV genes, the gene name in parentheses indicates the Zachau nomenclature. For all IGLV genes, the gene name in parentheses indicates the Kawasaki nomenclature. K, kappa chain; L, lambda chain; NA, not available.